Alnylam Pharmaceuticals Inc. reported its second quarter 2025 financial results, showing significant growth in revenues and operational performance. The company recorded total revenues of $773.7 million, reflecting a 17% increase compared to the same period in 2024. Notably, total net product revenues reached $672 million, marking a 64% rise compared to the previous year's second quarter, driven primarily by total TTR revenues of $544 million, which grew by 77%. The company's net loss per common share on a GAAP basis was $(0.51), a substantial increase in loss compared to $(0.13) in the second quarter of 2024. On a non-GAAP basis, the net income per common share was $0.34, down from $0.58 in the previous year. Alnylam has raised its 2025 guidance for TTR franchise net revenues to a range of $2.175 billion to $2.275 billion, and total net product revenues are projected to reach $2.65 billion to $2.8 billion, representing a $575 million or 27% increase at the midpoint. In terms of business developments, Alnylam achieved approximately 1,400 ATTR-CM patients on AMVUTTRA (vutrisiran) as of June 30, 2025, and obtained approvals for the treatment of ATTR-CM in the European Union, Brazil, the United Kingdom, and Japan. The company also initiated the TRITON-CM Phase 3 trial of Nucresiran in patients with Wild-Type or Hereditary ATTR-CM. Looking ahead, Alnylam plans to initiate several trials in the second half of 2025, including a Phase 3 cardiovascular outcomes trial of zilebesiran in collaboration with Roche, the TRITON-PN Phase 3 trial of nucresiran in hATTR-PN, and a Phase 2 trial of mivelsiran in Alzheimer's disease.